[144] Huron Consulting Group Inc. SEC Filing
Rhea-AI Filing Summary
Huron Consulting Group Inc. (HURN) – Form 144 filing. An affiliated seller, identified in prior sales as John F. McCartney and related entities, has filed notice to dispose of 800 common shares through Fidelity Brokerage Services on 01-Aug-2025. The shares carry an aggregate market value of $103,288, implying a price of roughly $129.11 each. HURN has 17.31 million shares outstanding; the planned sale therefore represents ~0.005% of the float, a de-minimis amount.
The stock to be sold was acquired via restricted-stock vesting on 03-Mar-2011 (300 sh), 01-Jan-2023 (6 sh) and 01-Jul-2024 (494 sh) as compensation. During the past three months, the filer and related trusts/foundations have already sold 2,400 shares in six transactions, generating gross proceeds of ≈$330.8 k at prices similar to the current market.
Investment view: The filing signals continued insider selling but in very small volumes relative to Huron’s capitalization, suggesting limited direct market impact. No indication of undisclosed adverse information is asserted in the certification, and no 10b5-1 plan date is supplied.
Positive
- None.
Negative
- None.
Insights
TL;DR – Insider plans to sell 800 HURN shares; volume immaterial.
The Form 144 shows further disposition by long-time director John F. McCartney and related entities. Even with prior three-month sales of 2,400 shares, cumulative volume remains <0.02 % of shares outstanding and unlikely to pressure liquidity. Nevertheless, insider selling amid no offsetting purchases may be read by some investors as a modest sentiment negative. There is no evidence of a pre-arranged 10b5-1 plan in this filing, which can heighten perception of discretionary selling. From a valuation standpoint, $130 share price implies ~16× 2024E EPS; the sale does not alter fundamentals. Impact: limited.
TL;DR – Routine Rule 144 notice; governance impact minimal.
The filing complies with Rule 144 and reconfirms that the seller asserts no non-public MNPI. Sale size is well below Rule 144 volume limits (1% of outstanding or average weekly volume), so regulatory risk is negligible. Absence of 10b5-1 plan disclosure suggests discretionary timing but does not, by itself, breach best-practice standards. Investors should monitor whether continued sales aggregate to a more meaningful level, yet today’s notice is procedurally routine.